[AAVL] Avalanche Biotechnologies, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization: 111.74 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 4.14 Change: 0 (0%)
Ext. hours: Change: 0 (0%)

chart AAVL

Refresh chart

Description: Avalanche Biotechnologies, Inc., a clinical-stage biotechnology company, focuses on discovering and developing novel gene therapies for the treatment of ophthalmic diseases based on its Ocular BioFactory platform. Its lead product candidate includes AVA-101, which is in a Phase I/IIa trial for the treatment of wet age-related macular degeneration (AMD). The company is also developing AVA-201, an anti-vascular endothelial growth factor gene therapy product candidate for the prevention of wet AMD; and AVA-311 that is in preclinical studies for the treatment of juvenile X-linked retinoschisis, a rare genetic disease of the retina with no approved therapy. Avalanche Biotechnologies, Inc. has a collaboration agreement with Regeneron Pharmaceuticals, Inc. research, develop, and commercialize gene therapy products. The company was founded in 2006 and is headquartered in Menlo Park, California.

Fundamental Ratios
Shares Outstanding26.99 M EPS-1.8 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 50.37% Sales Growth - Q/Q0% P/E-2.4
P/E To EPS Growth P/S156.51 P/BV0.42 Price/Cash Per Share
Price/Free Cash Flow-16.95 ROA-11.36% ROE-11.89% ROI
Current Ratio38.17 Quick Ratio Long Term Debt/Equity Debt Ratio0.03
Gross Margin Operating Margin-4343.22% Net Profit Margin-4463.09% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities138.97 M Cash From Investing Activities-88.78 M Cash From Operating Activities-7.74 M Gross Profit
Net Profit-9.51 M Operating Profit-9.56 M Total Assets292.69 M Total Current Assets291.13 M
Total Current Liabilities7.63 M Total Debt Total Liabilities13.01 M Total Revenue200 K
Technical Data
High 52 week41.4 Low 52 week4.03 Last close4.14 Last change-4.17%
RSI17.06 Average true range0.35 Beta1.18 Volume
Simple moving average 20 days-22.33% Simple moving average 50 days-21.29% Simple moving average 200 days-47.76%
Performance Data
Performance Week-17.03% Performance Month-18.66% Performance Quart-9.41% Performance Half-55.77%
Performance Year-87.78% Performance Year-to-date-56.51% Volatility daily5.14% Volatility weekly11.48%
Volatility monthly23.54% Volatility yearly81.53% Relative Volume0% Average Volume339.18 K
New High New Low

News

2016-11-09 09:09:03 | Adverum Biotechnologies to Present at Upcoming Investor Conferences

2016-11-08 16:19:15 | Adverum Biotechnologies, Inc. Reports Third Quarter 2016 Financial Results

2016-10-14 07:20:01 | Adverum Biotechnologies Provides Update on Alpha-1 Antitrypsin Deficiency Program

2016-10-14 07:20:01 | Adverum Biotechnologies, Inc. Announces New Executive Chair and CEO

2016-09-16 07:28:05 | Adverum Biotechnologies Presents Preclinical Data on Novel Gene Therapy Candidates for the Treatment of Wet AMD at The Retina Society 2016 Annual Meeting

2016-08-09 16:30:07 | Adverum Biotechnologies, Inc. Reports Second Quarter 2016 Financial Results

2016-08-09 07:20:16 | Adverum Biotechnologies and Editas Medicine Announce Collaboration to Explore Delivery of Genome Editing Medicines to the Eye

2016-07-07 16:31:08 | Adverum Biotechnologies Provides wet AMD Program Update

2016-06-13 08:49:04 | Adverum Biotechnologies Appoints Leone Patterson as Chief Financial Officer

2016-05-12 11:17:09 | AVALANCHE BIOTECHNOLOGIES CLOSES TRANSACTION WITH ANNAPURNA THERAPEUTICS AND FORMS NEW COMPANY, ADVERUM BIOTECHNOLOGIES

2016-05-12 07:10:04 | ADVERUM BIOTECHNOLOGIES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisiti

2016-05-10 17:08:22 | AVALANCHE BIOTECHNOLOGIES, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Other Events

2016-05-10 16:48:03 | Avalanche Biotechnologies’ Stockholders Vote in Favor of Annapurna Transaction

2016-05-09 10:16:02 | Avalanche AAVL Reports Wider-than-Expected Q1 Loss

2016-05-06 07:24:04 | Avalanche Biotechnologies, Inc. Reports First Quarter 2016 Financial Results

2016-05-06 07:12:49 | AVALANCHE BIOTECHNOLOGIES, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statemen

2016-05-06 07:10:41 | Avalanche Biotech reports 1Q loss

2016-04-27 07:11:31 | Avalanche Biotechnologies to Present at Upcoming Scientific Meetings

2016-04-14 09:22:00 | 5 Stocks Under $10 Set to Soar

2016-04-07 16:14:26 | AVALANCHE BIOTECHNOLOGIES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements

2016-03-15 06:08:08 | AVALANCHE BIOTECHNOLOGIES, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events

2016-03-10 16:17:55 | AVALANCHE BIOTECHNOLOGIES, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits

2016-03-10 13:04:27 | AVALANCHE BIOTECHNOLOGIES, INC. Financials

2016-03-07 16:56:17 | AVALANCHE BIOTECHNOLOGIES, INC. Files SEC form 8-K, Change in Directors or Principal Officers

2016-03-04 09:50:02 | Avalanche AAVL Reports Wider-than-Expected Loss in Q4

2016-03-04 06:13:00 | AVALANCHE BIOTECHNOLOGIES, INC. Files SEC form 10-K, Annual Report

2016-03-03 09:36:02 | Avalanche AAVL Posts Wider-than-Expected 4Q Loss

2016-03-03 08:07:38 | Avalanche Biotech reports 4Q loss

2016-03-03 07:24:09 | AVALANCHE BIOTECHNOLOGIES, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statemen

2016-03-02 15:40:08 | What's in Store for Avalanche AAVL This Earnings Season?

2016-02-25 14:33:00 | 4 Biotech Stocks Recommended by Citigroup Analysts

2016-02-22 16:17:35 | AVALANCHE BIOTECHNOLOGIES, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits

2016-02-19 09:38:00 | Avalanche Shareholders Push Back Against Gene Therapy Reboot Merger

2016-02-17 06:12:29 | AVALANCHE BIOTECHNOLOGIES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits

2016-02-16 16:12:29 | AVALANCHE BIOTECHNOLOGIES, INC. Files SEC form 8-K, Change in Directors or Principal Officers

2016-02-11 08:15:01 | Avalanche Biotechnologies AAVL Jumps: Stock Rises 10.1%

2016-02-02 17:28:10 | Avalanche AAVL Set to Acquire Annapurna Therapeutics

2016-02-02 06:04:01 | AVALANCHE BIOTECHNOLOGIES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements

2016-02-01 14:34:01 | Avalanche Restarts From Bottom

2016-02-01 13:01:55 | Avalance Biotechnologies Tumbles 14% Following Acquisition Announcement

2016-02-01 07:10:15 | Avalanche Biotechnologies and Annapurna Therapeutics Announce Proposed Merger

2015-11-20 07:26:15 | Avalanche Biotechnologies, Inc. Names Paul B. Cleveland as CEO

2015-08-13 16:48:56 | Avalanche Biotech reports 2Q loss

2015-06-16 17:31:11 | Avalanche Biotech plunges on results from eye drug study

2015-05-13 07:10:00 | Avalanche Biotech reports 1Q loss

2015-03-05 10:10:18 | Avalanche Biotech reports 4Q loss